|
Auriga Laboratories Obtains Rights to Market and Sell a New Product
Indicated for the Treatment of ADHD
Auriga
Laboratories, Inc. (OTCBB: ARGA), a specialty pharmaceutical
company, announced today the signing of a license agreement
with Outlook Pharmaceuticals, Inc., pursuant to which Auriga
will have the exclusive rights to market and sell a new
product indicated for the treatment of Attention Deficit
Hyperactivity Disorder (ADHD) in the United States. The new
product combines one of the most frequently prescribed drug
classes for this condition, in a unique dosage form previously
not available.
ADHD
treatments are one of the most frequently prescribed product
classes in the US with over 35 million prescriptions written
by physicians, generating estimated sales of over $3.5 billion
dollars in the U.S. annually.
The
product is expected to be approved by the Food and Drug
Administration in early 2008 and launch during the 2
nd Quarter
of 2008. “This Agreement solidifies Auriga’s commitment
to enhance our product portfolio with products approved using the
ANDA and 505(b)(2) NDA regulatory pathways,” said Philip S.
Pesin, CEO of Auriga.
About
Outlook Pharmaceuticals, Inc.
Outlook
Pharmaceuticals, Inc., is a privately held company
specializing in the development of branded prescription
products for the treatment of select central nervous system
disorders.
About
Auriga Laboratories(TM)
Auriga
Laboratories is a specialty pharmaceutical company building an
industry changing commission based-sales model. The company's
high-growth business model combines driving revenues through a
variable cost commission-based sales structure, acquisition of
proven brand names, introduction of new brands, and a
strategic development pipeline, all of which designed to
enhance its growing direct relationships with physicians
nationwide. Auriga's exclusive prescription and
over-the-counter product portfolio includes Aquoral™ for
the treatment of Xerostomia, Akurza™ ,
Xyral
| 
